News

Find News

Filter articles

Applied Filters

Showing 121 to 130 of 910 results

Sandoz to appeal against Amgen biosimilar ruling

US13-08-2019Sarah Morgan

Sandoz has confirmed that it plans to appeal against a decision that upheld the validity of two of Amgen’s patents for its arthritis treatment Enbrel, effectively blocking the launch of Sandoz’s biosimilar version.

Fed Circ affirms Eli Lilly victories over cancer drugs

US13-08-2019Sarah Morgan

The US Court of Appeals for the Federal Circuit last week affirmed two findings that Dr Reddy’s and Hospira had infringed Eli Lilly’s cancer drug Alimta.

Akebia Therapeutics and Par Pharma settle Auryxia suit

US07-08-2019Saman Javed

A subsidiary of Akebia Therapeutics has entered into a settlement agreement with Endo-owned Par Pharmaceutical.

Allergan to pay $2.7m to settle antitrust suit over Asacol

US06-08-2019Saman Javed

A subsidiary of Irish pharmaceutical company Allergan is to pay a combined total of $2.7 million to three organisations that were part of an antitrust class against the drugmaker.

Bausch Health resolves IP litigation with Teva

US02-08-2019Sarah Morgan

Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease. 

Alkermes settles with Amneal over opioid dependence treatment

US31-07-2019Sarah Morgan

Biopharmaceutical company Alkermes has entered into a settlement and licence agreement with generic maker Amneal Pharmaceuticals to resolve an inter partes review.

Teva to pay California $69m over pay-for-delay deals

US30-07-2019Saman Javed

The state of California has secured a $69 million settlement with Teva, which allegedly entered into collusive pay-for-delay agreements with generic competitors.

Pfizer off-patent division to merge with Mylan

UK29-07-2019Rory O'Neill

Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.

Celgene settles antitrust class-action for $55m

US25-07-2019Saman Javed

US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.

FDA opens US to Lyrica generics

US24-07-2019Sarah Morgan

The US Food and Drug Administration last week approved nine applications for the first generic versions of Pfizer’s Lyrica.

Showing 121 to 130 of 910 results

LSIPR